Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transducin-like enhancer protein 6 (TLE6)
- Target
- TLE6
- Molecular classification
- Transcriptional co-repressor, Subcortical maternal complex (SCMC) component, WD40 repeat protein, Other (not a receptor, enzyme, transporter, or typical therapeutic target)
01
Overview
Transducin-like enhancer protein 6 (TLE6) is a member of the Groucho/transducin-like enhancer of split family of transcriptional co-repressors, characterized as a core component of the subcortical maternal complex (SCMC) in mammalian oocytes and early embryos[1][3][6]. It consists of 581 amino acids, contains five WD40 repeat domains, and is critical for the regulation and maintenance of the actin cytoskeleton during oocyte maturation and symmetric zygotic cell division[1][2][4][6][7]. Loss of TLE6 results in failed embryogenesis beyond the two-cell stage, leading to preimplantation embryonic arrest and infertility in both animal models and humans[1][2][6][7]. TLE6 is not considered a classical therapeutic target (such as a receptor or enzyme), but pathogenic variants serve as genetic biomarkers for certain infertility syndromes[2][3][7].
- Other names
- TLE family member 6subcortical maternal complex memberFLJ14009GRG6OZEMA15PREMBLtransducin-like enhancer of split 6
02
Biological functions
Regulation of embryonic cell divisionStabilization of subcortical maternal complexRegulation of actin cytoskeleton in oocytes/zygotesRegulation of cell cycle, especially in germ cellsTranscriptional repression (in certain contexts)
03
Disease associations
Female infertility (early embryonic developmental arrest/premature ovarian failure)Oocyte/zygote/embryo maturation arrestPremature ovarian failureOther: rare Mendelian causes of infertility
04
Safety considerations
No therapeutic agents target TLE6; essential for embryonic development, so manipulation presents risk of embryonic/developmental lethality
05
Biomarkers
Pathogenic loss-of-function or missense variants (for diagnosis in infertility, especially preimplantation developmental arrest)
Beyond the preview
Go deeper on Transducin-like enhancer protein 6 (TLE6).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transducin-like enhancer protein 6 (TLE6).